Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.10
DGX's Cash-to-Debt is ranked lower than
91% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.33 vs. DGX: 0.10 )
Ranked among companies with meaningful Cash-to-Debt only.
DGX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.09 Max: N/A
Current: 0.1
Equity-to-Asset 0.46
DGX's Equity-to-Asset is ranked lower than
71% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. DGX: 0.46 )
Ranked among companies with meaningful Equity-to-Asset only.
DGX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.3  Med: 0.44 Max: 0.62
Current: 0.46
0.3
0.62
Interest Coverage 8.96
DGX's Interest Coverage is ranked lower than
68% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.14 vs. DGX: 8.96 )
Ranked among companies with meaningful Interest Coverage only.
DGX' s Interest Coverage Range Over the Past 10 Years
Min: 5.74  Med: 7.97 Max: 9.27
Current: 8.96
5.74
9.27
Piotroski F-Score: 8
Altman Z-Score: 3.81
Beneish M-Score: -2.64
WACC vs ROIC
6.82%
9.91%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 17.20
DGX's Operating Margin % is ranked higher than
87% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. DGX: 17.20 )
Ranked among companies with meaningful Operating Margin % only.
DGX' s Operating Margin % Range Over the Past 10 Years
Min: 13.22  Med: 16.93 Max: 20.64
Current: 17.2
13.22
20.64
Net Margin % 9.35
DGX's Net Margin % is ranked higher than
78% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.44 vs. DGX: 9.35 )
Ranked among companies with meaningful Net Margin % only.
DGX' s Net Margin % Range Over the Past 10 Years
Min: 5.07  Med: 8.3 Max: 11.88
Current: 9.35
5.07
11.88
ROE % 15.18
DGX's ROE % is ranked higher than
79% of the 213 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.56 vs. DGX: 15.18 )
Ranked among companies with meaningful ROE % only.
DGX' s ROE % Range Over the Past 10 Years
Min: 10.72  Med: 14.94 Max: 20.93
Current: 15.18
10.72
20.93
ROA % 6.98
DGX's ROA % is ranked higher than
78% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.39 vs. DGX: 6.98 )
Ranked among companies with meaningful ROA % only.
DGX' s ROA % Range Over the Past 10 Years
Min: 4.78  Med: 6.64 Max: 9.31
Current: 6.98
4.78
9.31
ROC (Joel Greenblatt) % 112.07
DGX's ROC (Joel Greenblatt) % is ranked higher than
93% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.92 vs. DGX: 112.07 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DGX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 88  Med: 116.04 Max: 143.99
Current: 112.07
88
143.99
3-Year Revenue Growth Rate 4.30
DGX's 3-Year Revenue Growth Rate is ranked lower than
57% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. DGX: 4.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DGX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 3.5  Med: 7.9 Max: 15.4
Current: 4.3
3.5
15.4
3-Year EBITDA Growth Rate -2.40
DGX's 3-Year EBITDA Growth Rate is ranked lower than
63% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.60 vs. DGX: -2.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DGX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -2.4  Med: 9.3 Max: 44.4
Current: -2.4
-2.4
44.4
3-Year EPS without NRI Growth Rate -5.30
DGX's 3-Year EPS without NRI Growth Rate is ranked lower than
58% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.00 vs. DGX: -5.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
DGX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 8.45 Max: 61.5
Current: -5.3
0
61.5
GuruFocus has detected 6 Warning Signs with Quest Diagnostics Inc $DGX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DGX's 30-Y Financials

Financials (Next Earnings Date: 2017-07-25)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:NAS:IDXX, NYSE:LH, OTCPK:SSMXY, NYSE:A, NYSE:Q, OTCPK:ERFSF, OTCPK:BMXMF, NAS:QGEN, NYSE:PKI, NAS:INCR, NAS:DXCM, NYSE:BIO, NAS:ICLR, NAS:BRKR, NYSE:CRL, OTCPK:CZMWY, NAS:PRAH, NAS:PRXL, NYSE:ALR, NAS:VWR » details
Traded in other countries:QDI.Germany,
Headquarter Location:USA
Quest Diagnostics Inc is the provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions.

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates about 90% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing at its national network of 2,000 patient service centers. The firm also runs a diagnostic solutions segment which provides clinical trials testing, risk assessment services, and information technology solutions.

Ratios

vs
industry
vs
history
PE Ratio 22.40
DGX's PE Ratio is ranked higher than
71% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.54 vs. DGX: 22.40 )
Ranked among companies with meaningful PE Ratio only.
DGX' s PE Ratio Range Over the Past 10 Years
Min: 9.09  Med: 17.18 Max: 31.26
Current: 22.4
9.09
31.26
Forward PE Ratio 19.72
DGX's Forward PE Ratio is ranked higher than
81% of the 36 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.57 vs. DGX: 19.72 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 22.40
DGX's PE Ratio without NRI is ranked higher than
72% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.74 vs. DGX: 22.40 )
Ranked among companies with meaningful PE Ratio without NRI only.
DGX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.48  Med: 15.52 Max: 22.41
Current: 22.4
9.48
22.41
Price-to-Owner-Earnings 27.79
DGX's Price-to-Owner-Earnings is ranked higher than
56% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 32.56 vs. DGX: 27.79 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
DGX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.27  Med: 25.95 Max: 129.96
Current: 27.79
12.27
129.96
PB Ratio 3.29
DGX's PB Ratio is ranked higher than
59% of the 210 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.94 vs. DGX: 3.29 )
Ranked among companies with meaningful PB Ratio only.
DGX' s PB Ratio Range Over the Past 10 Years
Min: 1.85  Med: 2.45 Max: 4.06
Current: 3.29
1.85
4.06
PS Ratio 2.08
DGX's PS Ratio is ranked higher than
72% of the 213 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. DGX: 2.08 )
Ranked among companies with meaningful PS Ratio only.
DGX' s PS Ratio Range Over the Past 10 Years
Min: 1.03  Med: 1.35 Max: 2.08
Current: 2.08
1.03
2.08
Price-to-Free-Cash-Flow 19.03
DGX's Price-to-Free-Cash-Flow is ranked higher than
67% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.07 vs. DGX: 19.03 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
DGX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.23  Med: 13.81 Max: 21.58
Current: 19.03
8.23
21.58
Price-to-Operating-Cash-Flow 14.09
DGX's Price-to-Operating-Cash-Flow is ranked higher than
75% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.63 vs. DGX: 14.09 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
DGX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.98  Med: 10.88 Max: 14.09
Current: 14.09
6.98
14.09
EV-to-EBIT 13.76
DGX's EV-to-EBIT is ranked higher than
83% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 13.76 )
Ranked among companies with meaningful EV-to-EBIT only.
DGX' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.2  Med: 10.4 Max: 15.2
Current: 13.76
7.2
15.2
EV-to-EBITDA 11.63
DGX's EV-to-EBITDA is ranked higher than
79% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.45 vs. DGX: 11.63 )
Ranked among companies with meaningful EV-to-EBITDA only.
DGX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.1  Med: 8.6 Max: 11.8
Current: 11.63
6.1
11.8
PEG Ratio 4.25
DGX's PEG Ratio is ranked lower than
59% of the 49 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.17 vs. DGX: 4.25 )
Ranked among companies with meaningful PEG Ratio only.
DGX' s PEG Ratio Range Over the Past 10 Years
Min: 0.81  Med: 2.09 Max: 5.98
Current: 4.25
0.81
5.98
Shiller PE Ratio 26.95
DGX's Shiller PE Ratio is ranked higher than
74% of the 31 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 47.43 vs. DGX: 26.95 )
Ranked among companies with meaningful Shiller PE Ratio only.
DGX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.39  Med: 20.16 Max: 38.66
Current: 26.95
14.39
38.66
Current Ratio 1.58
DGX's Current Ratio is ranked lower than
71% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. DGX: 1.58 )
Ranked among companies with meaningful Current Ratio only.
DGX' s Current Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.28 Max: 2.15
Current: 1.58
0.74
2.15
Quick Ratio 1.50
DGX's Quick Ratio is ranked lower than
66% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. DGX: 1.50 )
Ranked among companies with meaningful Quick Ratio only.
DGX' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.2 Max: 2.03
Current: 1.5
0.7
2.03
Days Inventory 6.34
DGX's Days Inventory is ranked higher than
93% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 82.10 vs. DGX: 6.34 )
Ranked among companies with meaningful Days Inventory only.
DGX' s Days Inventory Range Over the Past 10 Years
Min: 6.34  Med: 7.69 Max: 8.46
Current: 6.34
6.34
8.46
Days Sales Outstanding 46.40
DGX's Days Sales Outstanding is ranked higher than
72% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.30 vs. DGX: 46.40 )
Ranked among companies with meaningful Days Sales Outstanding only.
DGX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.51  Med: 43.71 Max: 48.01
Current: 46.4
40.51
48.01
Days Payable 20.54
DGX's Days Payable is ranked lower than
84% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.24 vs. DGX: 20.54 )
Ranked among companies with meaningful Days Payable only.
DGX' s Days Payable Range Over the Past 10 Years
Min: 16.4  Med: 18.43 Max: 21.87
Current: 20.54
16.4
21.87

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.53
DGX's Dividend Yield % is ranked higher than
69% of the 98 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.90 vs. DGX: 1.53 )
Ranked among companies with meaningful Dividend Yield % only.
DGX' s Dividend Yield % Range Over the Past 10 Years
Min: 0.62  Med: 0.9 Max: 2.46
Current: 1.53
0.62
2.46
Dividend Payout Ratio 0.34
DGX's Dividend Payout Ratio is ranked higher than
50% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.34 vs. DGX: 0.34 )
Ranked among companies with meaningful Dividend Payout Ratio only.
DGX' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.1  Med: 0.17 Max: 0.45
Current: 0.34
0.1
0.45
3-Year Dividend Growth Rate 10.60
DGX's 3-Year Dividend Growth Rate is ranked lower than
53% of the 34 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.20 vs. DGX: 10.60 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
DGX' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 3.15 Max: 55.4
Current: 10.6
0
55.4
Forward Dividend Yield % 1.64
DGX's Forward Dividend Yield % is ranked higher than
71% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.91 vs. DGX: 1.64 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 6.46
DGX's 5-Year Yield-on-Cost % is ranked higher than
93% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.42 vs. DGX: 6.46 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
DGX' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.62  Med: 3.8 Max: 10.39
Current: 6.46
2.62
10.39
3-Year Average Share Buyback Ratio 1.60
DGX's 3-Year Average Share Buyback Ratio is ranked higher than
93% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. DGX: 1.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DGX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -16.9  Med: 1.5 Max: 7
Current: 1.6
-16.9
7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.52
DGX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
76% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. DGX: 1.52 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
DGX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.65  Med: 0.9 Max: 3.77
Current: 1.52
0.65
3.77
Price-to-Intrinsic-Value-DCF (Earnings Based) 2.09
DGX's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
50% of the 18 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.07 vs. DGX: 2.09 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.54
DGX's Price-to-Median-PS-Value is ranked lower than
77% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. DGX: 1.54 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DGX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.24  Med: 1.03 Max: 1.66
Current: 1.54
0.24
1.66
Earnings Yield (Greenblatt) % 7.26
DGX's Earnings Yield (Greenblatt) % is ranked higher than
92% of the 238 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.52 vs. DGX: 7.26 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DGX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 6.6  Med: 9.6 Max: 13.8
Current: 7.26
6.6
13.8
Forward Rate of Return (Yacktman) % 7.86
DGX's Forward Rate of Return (Yacktman) % is ranked higher than
52% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.56 vs. DGX: 7.86 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
DGX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 7.8  Med: 14.3 Max: 25.1
Current: 7.86
7.8
25.1

More Statistics

Revenue (TTM) (Mil) $7,551.00
EPS (TTM) $ 4.96
Beta0.96
Short Percentage of Float4.95%
52-Week Range $77.29 - 110.65
Shares Outstanding (Mil)136.83

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 7,679 7,834 8,024
EPS ($) 5.51 5.97 6.13
EPS without NRI ($) 5.51 5.97 6.13
EPS Growth Rate
(Future 3Y To 5Y Estimate)
7.48%
Dividends per Share ($) 1.78 1.97 2.15
» More Articles for DGX

Headlines

Articles On GuruFocus.com
Paulson Dives Deeper Into Valeant With Increased Holding Jun 27 2017 
US Market Indexes Lower, Technology Stock Volatility a Factor Jun 27 2017 
General Mills to Release 4th-Quarter, Full-Fiscal 2017 Results Jun 27 2017 
Warren Buffett Interprets the State of the Economy on PBS Newshour Jun 27 2017 
Office Space Provider Is a Good Stock to Follow Jun 27 2017 
Don't Lose Your Faith in Cisco Systems Jun 27 2017 
The Future of Value Investing Jun 27 2017 
Quotes From 2 of the World's Greatest Value Investors Jun 27 2017 
Extracts From the Bible of Value Investing Jun 27 2017 
Autonomous Driving Offers No Easy Path for Investors Jun 27 2017 

More From Other Websites
Walgreens Partners With LabCorp In New Diagnostic Testing Deal Jun 28 2017
Quest Diagnostics to Buy Outreach Lab Service in Cape Cod Jun 28 2017
Quest Diagnostics Announces Intent to Acquire Cape Cod Healthcare Outreach Laboratory Business in... Jun 27 2017
Walmart To Partner With Quest Diagnostics To Offer In-Store Lab Work Jun 27 2017
Amazon could push more pharmacies into offering lab tests Jun 27 2017
Quest Diagnostics Enhances Blueprint for Athletes Service Jun 26 2017
Why Quest Diagnostics (DGX) is a Suitable Pick for Investors Jun 22 2017
Quest Diagnostics Adds Custom Coaching, At-Home Collection to Expand Blueprint for Athletes™... Jun 22 2017
Apple is working with this small start-up to change how we track our health Jun 19 2017
Quest Diagnostics to Buy 2 Labs, Grow in Oncology Space Jun 13 2017
Quest Diagnostics to Form Precision Oncology Center of Excellence Through Acquisition of Two Texas... Jun 12 2017
Data Diagnostics Wins 2017 MedTech Breakthrough Award Jun 08 2017
New Study: Physicians Lack the Right Tools to Close Costly Gaps in Healthcare Jun 06 2017
Quest Diagnostics Pushes Beyond Lab Tests With Treatment Prediction May 26 2017
Quest Diagnostics Hits a 52-Week High on Solid Prospects May 26 2017
3 Top Dividend Stocks in Gene Sequencing May 24 2017
Quest Diagnostics (DGX) Up 1.8% Since Earnings Report: Can It Continue? May 23 2017
Quest Diagnostics Poised on Solid Q1 Results Despite Woes May 22 2017
These states have the most workers using illegal drugs May 17 2017
[$$] More American Workers Are Testing Positive for Drugs May 16 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}